Evoke Pharma (EVOK) Registration Filing summary

Company overview and business model

• Focuses on developing and commercializing drugs for gastrointestinal disorders, with Gimoti nasal spray as its sole product, approved for diabetic gastroparesis and launched in the US in October 2020 through a partnership with Eversana Life Science Services.

• Gimoti offers a nasally-administered alternative to oral metoclopramide, reducing healthcare utilization and costs for patients with diabetic gastroparesis.

• Operations have been primarily funded through equity and debt financings, with modest sales generated since commercial launch.

Financial performance and metrics

• Reported net loss of $7.8 million for 2023 and $1.6 million for Q1 2024, with net loss per share of $27.97 and $2.09, respectively, after a 1-for-12 reverse stock split.

• Net tangible book value as of June 30, 2024, was $2.7 million ($3.63 per share); full warrant exercise would increase this to $23.8 million ($5.96 per share).

Use of proceeds and capital allocation

• Proceeds from warrant exercises (up to $21.2 million if fully exercised) will be used for working capital, general corporate purposes, and commercialization activities.

• May allocate a portion to in-licensing, acquisitions, or investments in complementary businesses, though no current commitments exist.